Agoracom Blog
«
»

AGORACOM Small Cap 60: Valeo Pharma $VPH.ca $VPHIF An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 1:43 PM on Friday, January 8th, 2021

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

Hub On AGORACOM / Corporate Profile

Tags: , , , , , , , , , , , , ,

This entry was posted on Friday, January 8th, 2021 at 1:43 pm and is filed under AGORACOM Small Cap 60, All Recent Posts, Valeo Pharma Inc. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.